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Abstract
Background: There are no licensed vaccines available against Moraxella catarrhalis, a significant human respiratory
pathogen. Lipooligosaccharide (LOS) based conjugate vaccines derived from individual serotype M. catarrhalis only showed
partial protection coverage. A vaccine combining LOS conjugates of two or three serotypes might provide a broader
protection.
Methods: Mice were immunized intranasally with the combined conjugates consisting of LOS from serotype A and B or
serotype A, B, and C followed by challenge with different M. catarrhalis strains of three serotypes. Mouse lungs, nasal
washes, and sera were collected after each challenge for bacterial counts, histological evaluation, cytokine profiles, antibody
level and binding activity determinations.
Results: Intranasal administration of the combined LOS conjugates not only enhanced pulmonary bacterial clearance of all
three serotypes of M. catarrhalis strains in vaccinated mice, but also elevated serotype-specific anti-LOS immunoglobulin
(Ig)A and IgG titers in nasal wash and serum respectively. Mice vaccinated with the combined LOS conjugates also showed
increased interferon (IFN)-c, interleukin (IL)-12, and IL-4 in the lungs after challenges. Compared to the control group, mice
immunized with the combined LOS conjugates also showed reduced lung inflammation after M. catarrhalis infections. The
hyperimmune sera induced by the combined conjugates exhibited a broad cross-reactivity toward all three serotypes of M.
catarrhalis under transmission electron microscopy.
Conclusions: The combined vaccine of serotype A and B LOS conjugates provides protection against most M. catarrhalis
strains by eliciting humoral and cellular immune responses.
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Introduction
Moraxella catarrhalis is a Gram-negative aerobic diplococcus that
causes respiratory illness exclusively in humans. It is responsible
for 10% – 20% of all episodes of otitis media in infants and
children [1,2]. Approximately 80% of children experience at least
one episode of otitis media by the age of 3 years [3]. Otitis media
accounts for 24.5 million physician visits, more than 13 million
antibiotic prescriptions, and approximately $6 billion in health
care costs in the United States annually [3,4]. In addition, M.
catarrhalis is also responsible for an estimated 2 – 4 million
exacerbations of chronic obstructive pulmonary disease (COPD) in
the elderly annually [2]. Prevention of M. catarrhalis infections by
effective vaccination thus would potentially have a significant
impact on both public health and the economy.
However, there is no licensed vaccine for M. catarrhalis except
that a number of M. catarrhalis vaccine candidates are under
development or clinical testing [5–7]. Most of these vaccine
candidates are designed to target adhesion molecules in the outer
membrane of M. catarrhalis such as M. catarrhalis immunoglobulin
D-binding protein (MID) [8], the ubiquitous surface protein A
(UspA) [9], and catarrhalis outer membrane protein B (CopB)
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candidates are immunogenic, their efficiency is limited by
antigenic heterogeneity [5]. The lipooligosaccharide (LOS) is the
carbohydrate structure in the outer membrane of M. catarrhalis.
Being a major virulence factor of M. catarrhalis, LOS induces
excessive inflammation via a Toll-like receptor 4 (TLR4) and
CD14 dependent pathway [11]. The structures of LOS are
conserved among 95% of known M. catarrhalis strains and clinical
isolates [12,13]. Based on the LOS structures (Figure 1) [14–16],
M. catarrhalis can be categorized into three serotypes: A, B, and C
accounting for 61.3%, 28.8%, and 5.3% of the 302 strains tested
[12]. Monoclonal antibodies specific for serotype A LOS have
been reported to cross-react with serotype C LOS [13]. We have
shown that M. catarrhalis LOS-based conjugate vaccine candidates
from three individual serotypes were immunogenic in vivo, but
were only able to elicit bactericidal activity toward a portion of M.
catarrhalis strains and clinical isolates [17–19]. Immunization with a
LOS conjugate derived from serotype A protects against
homologous and heterologous challenges including serotype A
strains and a serotype C strain but not a serotype B strain in a
mouse pulmonary clearance model [20,21]. Similarly, immuniza-
tion with a LOS conjugate derived from serotype B or C alone has
been shown to protect against only partial M. catarrhalis strains in
our preliminary mouse pulmonary clearance study.
Based on these findings, we hypothesized that a combination of
LOS conjugates from two or three serotypes would protect against
most M. catarrhalis strains. To test this, we vaccinated mice with the
combined M. catarrhalis LOS conjugates consisting of serotype A
and B or serotype A, B, and C via intranasal route. The protection
elicited by the combined LOS conjugates against homologous and
heterologous strains of M. catarrhalis was evaluated in a mouse
pulmonary clearance model. Our primary goal was to determine
the optimal conjugate combination with the maximum protection
against all three serotypes of M. catarrhalis in mice.
Materials and Methods
Ethics statement
All experiments involving mice were performed according to the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. Protocols
were reviewed and approved by institutional review boards at the
National Institutes of Health (Permit Number: 1158).
Bacterial strains
M. catarrhalis strain O35E (serotype A) was kindly provided by
Eric J. Hansen (the University of Texas, Dallas, TX) and strain
25238 (serotype A) was purchased from the American Type
Culture Collection (Manassas, VA). M. catarrhalis serotype B strains
26397 and 26400, and serotype C strains 26404 and 26391 were
obtained from the Culture Collection of the University of
Goteborg, Department of Clinical Bacteriology, Goteborg,
Sweden.
Conjugate vaccines
Purification of LOSs from prototype strains 25238 (A), 26397
(B), and 26404 (C), detoxification of the LOSs, and conjugation of
detoxified LOSs (dLOSs) to the carrier tetanus toxoid (TT) were
performed for each serotype LOS individually as described [17–
19]. The synthesized dLOS-TT from 25238, 26397, or 26404 was
designated as conjugate A, B, or C, respectively. The composition
of the conjugates is described in Table 1. The combination of
conjugate A physically mixed with conjugate B in the equal
amount and the combination of conjugate A physically mixed with
conjugate B and conjugate C in the equal amount were named as
conjugates AB and ABC, respectively.
Immunizations
Six to 8 weeks old female BALB/c mice were obtained from
Taconic Farms Inc. (Germantown, NY). Cholera toxin (List
Biological Laboratories, Campbell, CA) was used as the mucosal
adjuvant at 1 mg/dose/mouse either alone or in the combination
Figure 1. Schematic structures of the LOS moieties on the surface of M. catarrhalis. Three main serotypes, A, B and C, are presented with
different R groups [14–16]. Abbreviations: Gal, galactose; Kdo, 3-deoxy-D-manno-octulosonic acid; Glc, glucose; GlcNAc, N-acetyl-D-glucosamine; p,
pyranose.
doi:10.1371/journal.pone.0029553.g001
Table 1. Composition of conjugate vaccines.
Conjugate
Concentration
(mg/ml) dLOS/TT molar ratio
a
dLOS TT
25238 dLOS-TT (A) 318.9 419.4 38
26397 dLOS-TT (B) 665.2 700.6 47
26404 dLOS-TT (C) 503.3 659.6 38
aExpressed as moles of dLOS per mole of TT protein, with molecular weights of
3,000 Da for dLOS and 150,000 Da for TT.
doi:10.1371/journal.pone.0029553.t001
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carbohydrate per dose per mouse). Mice (8 – 10 per group) were
anesthetized intraperitoneally with 0.1 ml of 2% ketamine (Fort
Dodge Laboratories, Inc., Fort Dodge, IA) and 0.2% xylazine
(Miles Inc., Shawnee Mission, KS) in 0.9% NaCl. A total of 18 ml
of each vaccine preparation was slowly instilled through a
micropipette into both nares of each mouse. Mice were
immunized weekly for a total of 4 weeks.
Bacterial challenge and sampling
One week after the last booster, mice were challenged with
aerosolized M. catarrhalis strains 25238 (A), O35E (A), 26397 (B),
26400 (B), 26404 (C), or 26391 (C) at 5610
8 to 1610
9 CFU/ml
in an inhalation exposure system (Glas-Col, LLC, Terre Haute,
IN) as described [22]. At 6 h post-challenge, mice were
euthanized. Sera and nasal washes were collected for antibody
detection. A subset of mouse lungs were harvested and
homogenized in 1 ml of phosphate buffered saline (PBS) with a
Precellys 24 homogenizer (Bertin Technologies, Paris, France).
Serially diluted lung homogenates were cultured on chocolate
agar plates overnight at 37uCw i t h5 %C O 2 to determine colony
forming unit (CFU) counts. The rest of lung homogenates were
then frozen for cytokine profiles. Another subset of mouse lungs
were harvested and fixed in 10% neutral formaldehyde for
histological assessment.
Enzyme-linked immunosorbent assay (ELISA)
The 96-well plates were coated with LOS of strains 25238 (A),
26397 (B), or 26404 (C) at 10 mg/ml. The anti-LOS specific IgA in
nasal washes and IgG in sera were determined by ELISA as
described [17] and were expressed as the reciprocal of the highest
serum dilution. Specific mouse hyperimmune sera against the
whole cells of strain 25238 (A), 26397 (B), or 26404 (C) were used
as references [17–19].
Cytokine determination
The inflammatory cytokines including interferon (IFN)-c,
interleukin (IL)-12 (total), IL-4, tumor necrosis factor (TNF)-a,
and mouse keratinocyte chemoattractant (mKC) in the lung
homogenates following challenges were quantified using a mouse
TH1/TH2 9-Plex Assay Ultra-Sensitive Kit according to the
manufacturer’s instructions and analyzed in a SECTOR imager
2400 (Meso Scale Discovery, Gaithersburg, MD).
Histological evaluation
Fixed mouse lungs were embedded in paraffin, sectioned,
mounted on slides, and stained with hematoxylin and eosin
(H&E). The slides were then observed and imaged under an
Olympus IX71 microscope with a digital camera (Olympus
America Inc., Miami, FL). Lung sections were scored for lung
injury, including the following: (1) intra-alveolar infiltration of
inflammatory cells, (2) thickness of the alveolar wall, (3) alveolar
hemorrhage, and (4) intra-alveolar proteinaceous exudate. The
items were semi-quantitatively scored as none, minimal, light,
moderate, or severe (score 0, 1, 2, 3, or 4, respectively) by a
pathologist blinded to the experimental groups. The combined
score of all four parameters was taken for each field. Ten
randomly chosen fields from each animal with approximately the
same number of alveoli were analyzed on each slide at 6400
magnification. The lung injury score was obtained by averaging
the scores of all the fields from each animal and 6 mice per group
were inspected.
Immunoelectron microscopy of bacteria
Formvar-coated 200-mesh grids (Electron Microscopy Sciences,
Hatfield, PA) were floated on the suspension of strain 25238 (A),
26397 (B), or 26404 (C) in PBS and blotted dry. Grids were then
incubated with sera from mice intranasally immunized with the
combined conjugates AB or the corresponding pre-immune sera
(1:400 dilution in PBS with 0.5% BSA) at room temperature for
30 min. Subsequently, the grids were incubated with gold (5-nm
diameter)-conjugated goat anti-mouse IgG (Ted Pella, Inc.,
Redding, CA, 1:20 dilution in PBS with 0.5% BSA) for 60 min.
The grids were blotted and washed 3 times with PBS between
steps. The bacteria were then negatively stained with a mixture of
equal volumes of 2% ammonium acetate and 2% ammonium
molybdate (Sigma, St. Louis, MO). The grids were viewed under a
JEOL JEM-1010 transmission electron microscope (JEOL Ltd.,
Tokyo, Japan).
Statistical analysis
The geometric mean (GM) of the anti-LOS specific IgA and
IgG titers from n independent observations plus/minus (6)
standard deviations (SD) were determined. The pulmonary levels
of viable residual bacteria counts were logarithm transformed
((log)10 CFU) before being subjected to one-way analysis of
variance (ANOVA). The differences in the lung cytokines and the
differences in the pathological lung injury scores among different
groups were determined by ANOVA. A P value less than 0.05 was
considered significant. A nonparametric Spearman correlation test
was employed to analyze the correlations among the residual
bacterial counts, antibodies, and pulmonary cytokine levels.
Results
Bacterial clearance in the mouse lungs
Figure 2 shows the pulmonary bacterial clearance in immunized
mice after challenge with different M. catarrhalis strains (Fig. 2).
Compared to adjuvant immunized control group, intranasal
vaccination with the combined conjugates AB or ABC plus
adjuvant significantly reduced the pulmonary bacterial burdens by
84% – 96% in immunized mice following challenges with three
serotypes of M. catarrhalis (Fig. 2). However, the addition of
conjugate C in the vaccine mixture showed no obvious benefit in
pulmonary clearance of M. catarrhalis including serotype C strains
when compared to the mice receiving only the combined
conjugates AB (Fig. 2).
Mucosal and systemic antibody responses
Intranasal immunization of the combined LOS conjugates plus
adjuvant significantly increased anti-M. catarrhalis LOS serotype-
specific IgA levels in nasal wash (conjugates AB plus adjuvant vs
adjuvant alone: 2.8 – 7.7 folds; conjugates ABC plus adjuvant vs
adjuvant alone: 5.4 – 28.4 folds) following challenges (Table 2).
Furthermore, intranasal administration of the combined LOS
conjugates plus adjuvant also enhanced serotype-specific IgG
levels in serum (conjugates AB plus adjuvant vs adjuvant alone: 2.9
– 10.0 folds; conjugates ABC plus adjuvant vs adjuvant alone: 8.6
– 34.1 folds). The higher levels of nasal IgA and serum IgG
produced, the lower levels of viable bacteria recovered in the lungs
of the vaccinated mice following challenges with all three serotypes
of M. catarrhalis strains (r=20.3532, P,0.0001 for nasal IgA;
r=20.4195, P,0.0001 for serum IgG). In general, administration
of the combined conjugates ABC elicited higher levels of anti-M.
catarrhalis LOS specific IgA in nasal wash and IgG in serum than
the combined conjugates AB (Table 2).
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Following challenges with three serotypes of M. catarrahlis strains,
the pulmonary levels of IFN-c, IL-12, and IL-4 were dramatically
elevated in the mice receiving the intranasal vaccination of the
combined LOS conjugates plus adjuvant (Fig. 3A, 3B, and 3C).
Meanwhile, the levels of mKC and TNF-a in the same lung
homogenates were also significantly reduced when compared to
adjuvant administered controls (Fig. 3D and 3E). The elevated
pulmonary IFN-c, IL-12, and IL-4 levels positively correlated with
the increased nasal wash IgA titers (r=0.2152, P,0.01 for IFN-c;
r=0.3060, P,0.001 for IL-12) and serum IgG titers (r=0.3034,
P,0. 001 for IFN-c; r=0.3707, P,0.0001 for IL-12; r=0.2032,
P,0.05 for IL-4) in mice that had been immunized with the
combined conjugates AB or ABC plus adjuvant. Moreover, the
reduced pulmonary levels of inflammatory mKC and TNF-a also
significantly correlated with the decreased bacterial recovery in the
same lung homogenates of the mice receiving the combined LOS
conjugates plus adjuvant (r=0.6380, P,0.0001 for mKC;
r=0.6239, P,0.0001 for TNF-a).
Histological changes in the lungs of vaccinated mice
after challenges
Unlike the normal mouse lung architecture (Fig. 4A), the lungs
of the adjuvant alone administered mice exhibited prominent
Figure 2. Pulmonary bacterial recovery after challenges with three serotypes of M. catarrhalis. Mice (8 – 10 per group) were vaccinated
intranasally (1 dose per week, 4 doses in total) with either the adjuvant cholera toxin alone (1 mg/dose/mouse) or the combined conjugates AB or
ABC (2.5 mg of each carbohydrate per dose per mouse) plus adjuvant. One week after the last booster, mice were challenged with aerosolized M.
catarrhalis including 25238 (type A), O35E (type A), 26397 (type B), 26400 (type B), 26404 (type C), or 26391 (type C) (5610
8 to 1610
9 CFU/ml). Mouse
lungs were harvested at 6 h after the challenge for bacterial counts. The viable bacteria are expressed as the mean of CFUs 6 standard error of the
mean (SEM). *P,0.05 indicates the significant difference vs adjuvant control by ANOVA.
doi:10.1371/journal.pone.0029553.g002
Table 2. Antibody responses of mice vaccinated with the combined conjugates after challenges with M. catarrhalis strains.
Challenge Strain Antibody class GM (± SD range) of antibody titers
a
Adjuvant Conjugates AB+Adjuvant Conjugates ABC+Adjuvant
25238 (A) Nasal wash IgA 1.3 (0.8–2.2) 8.1 (0.4–183.8) 7.2 (1.4–36.6)
Serum IgG 1.0 (1.0) 6.5 (0.4–116.0) 33.6 (1.7–653.0)
O35E (A) Nasal wash IgA 1.0 (1.0) 3.6 (0.9–14.5) 28.4 (2.3–343.7)
Serum IgG 1.3 (0.6–2.9) 4.3 (0.4–50.5) 41.9 (2.6–688.0)
26397 (B) Nasal wash IgA 1.5 (0.9–2.7) 4.2 (1.1–16.5) 8.1 (0.9–70.2)
Serum IgG 1.1 (0.8–1.7) 7.2 (0.4–134.0) 17.4 (0.3–904.4)
26400 (B) Nasal wash IgA 1.1 (0.8–1.7) 3.3 (0.4–25.6) 15.6 (1.1–221.4)
Serum IgG 1.0 (1.0) 10.0 (0.5–200.8) 19.4 (0.4–874.6)
26404 (C) Nasal wash IgA 2.6 (0.6–11.6) 14.7 (1.7–124.1) 65.0 (7.3–578.1)
Serum IgG 1.1 (0.8–1.7) 4.3 (0.3–67.4) 37.5 (3.7–381.6)
26391 (C) Nasal wash IgA 1.5 (0.7–3.4) 11.5 (1.2–109.0) 30.1 (2.0–454.4)
Serum IgG 1.3 (0.8–2.2) 3.8 (0.6–25.2) 11.2 (1.5–82.2)
aMice (8 – 10 per group) were vaccinated intranasally (1 dose per week, 4 doses in total) with either the adjuvant cholera toxin alone (1 mg/dose/mouse) or the
combined conjugates AB or ABC (2.5 mg of each carbohydrate per dose per mouse) plus adjuvant. One week after the last vaccination, mice were challenged with an
aerosol of indicated M. catarrhalis strain (5610
8 to 1610
9 CFU/ml). The nasal washes and sera were harvested at 6 h after the challenge for antibody detection. Data
are presented as geometric mean (GM) titer 6 standard deviation (SD).
doi:10.1371/journal.pone.0029553.t002
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challenges (Fig. 4B). However, the M. catarrhalis induced
pulmonary infiltration of inflammatory cells was diminished in
the mice that had been vaccinated with the combined conjugates
AB plus adjuvant (Fig. 4C). Consistently, the adjuvant alone
immunized mice displayed severe lung injury when compared to
naive mice (P,0.05) (Fig. 4D). On the contrary, vaccination with
the combined conjugates AB plus adjuvant significantly reduced
the score of acute lung injury in mice (P,0.05 vs adjuvant alone,
Fig. 4D) following M. catarrhalis challenges. In addition, a robust
lymphoproliferation along with the formation of focally propagat-
ed lymphocytes were observed in the subepithelia of trachea and
bronchi of the mice immunized with the conjugates AB plus
adjuvant followed by M. catarrhalis challenges (Fig. 4C). In contrast,
the lymphocytic proliferation was not found in the lungs of naive
mice and the lungs of adjuvant only immunized mice after the
challenges (Fig. 4A and 4B). The mice vaccinated with the
conjugates ABC plus adjuvant showed the similar lung histological
changes as those of the mice receiving the conjugates AB plus
adjuvant after M. catarrhalis challenges (data not shown).
Immunoelectron microscopy of M. catarrhalis
The cross-reactivity of anti-M. catarrhalis LOS specific hyperim-
mune mouse sera generated by vaccination with the combined
conjugates AB plus adjuvant were further characterized by
immunoelectron microscopy. As shown in Fig. 5, electron-dense
gold particles clearly scattered across the surfaces of all three
serotypes of M. catarrhalis strains including 25238 (type A, Fig. 5A),
26397 (type B, Fig. 5B), and 26404 (type C, Fig. 5C) after pre-
incubation with the hyperimmune sera of mice vaccinated with the
combined conjugates AB plus adjuvant. In contrast, the whole cells
of 25238 pre-incubated with the corresponding mouse pre-
Figure 3. Pulmonary cytokine levels after challenges with three serotypes of M. catarrhalis. Mice were vaccinated (1 dose per week, 4
doses in total) with either the adjuvant cholera toxin alone (1 mg/dose/mouse) or the combined conjugates AB or ABC (2.5 mg of each carbohydrate
per dose per mouse) plus adjuvant. One week after the last booster, mice were challenged with aerosolized M. catarrhalis including 25238 (type A),
O35E (type A), 26397 (type B), 26400 (type B), 26404 (type C), or 26391 (type C) (5610
8 to 1610
9 CFU/ml). At 6 h after the challenge, mouse lungs
were harvested and homogenized for detection of IFN-c, IL-12, IL-4, mKC, and TNF-a. Data are presented as mean 6 SEM. *P,0.05 indicates the
significant difference vs adjuvant control by ANOVA. Note: Pulmonary IL-4 in mice immunized with adjuvant only was below the detection limit after
M. catarrhalis 26391 challenge.
doi:10.1371/journal.pone.0029553.g003
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(Fig. 5D).
Discussion
LOS is a major virulence factor located in the outer membrane
of M. catarrhalis. It can potentially induce excessive inflammation
via cellular cross-talk [11]. Unlike the outer membrane proteins
such as MID, UspA, and CopB that show a great plasticity in their
antigenicity [6,23], the structures of LOS are highly conserved
within each of the three serotypes of M. catarrhalis [12,13]. Thus
LOS has the great potential to be developed into carbohydrate-
based conjugate vaccines against M. catarrhalis infections. Previ-
ously we have reported that LOS based conjugate vaccines derived
from individual serotypes of M. catarrhalis were highly immuno-
genic in vivo, but could protect against only a fraction of M.
catarrhalis strains [17–21]. Hence, we hypothesized that a
combination of LOS conjugates of two or three serotypes could
provide a broader protection against most of the known M.
catarrhalis strains.
In the present study, we demonstrated that intranasal
immunization of the combined LOS conjugates from serotype A
and B or from serotype A, B, and C led to a significant reduction
in the bacterial burden in the lungs of M. catarrhalis infected mice.
Mice vaccinated with the combined LOS conjugates not only
efficiently cleared M. catarrhalis of the same serotype out of the
respiratory system but also the strains of different serotypes.
Interestingly, both the combined LOS conjugates AB and ABC
demonstrated a similar efficiency in clearing not only serotype A
and B strains but also serotype C bacteria. This is not surprising
since there is a high cross-reactivity in the antibodies against the
LOS structures between serotype A and C strains [13]. Serotype A
and B M. catarrhalis are the major clinical isolates and serotype C
comprises less than 6% of M. catarrhalis strains identified so far.
The supplement of serotype C conjugate into conjugates AB
combination may induce additional homologous or cross-reactive
heterologous antibodies against each serotype LOS antigen.
Therefore, the mice receiving the ABC conjugates generally
showed higher levels of serum IgG and nasal IgA responses than
the mice administered with the AB conjugates. However, our
results indicated that intranasal vaccination with the combined
conjugates consisting of serotype A and B LOS was efficient to
combat the tested M. catarrhalis strains of all three serotypes. The
addition of serotype C conjugate into the conjugates AB
combination did not further enhance the efficiency of pulmonary
bacterial clearance in the current study. Our results also suggest
that the combined LOS conjugates AB could be a potent and cost-
effective mucosal vaccine candidate to fight against M. catarrhalis
infections.
As revealed by the histology data, intranasal immunization of
the combined LOS conjugates also resulted in a robust
proliferation of mucosal lymphocytes in the airway branches in
vaccinated mice. These mucosal lymphocytes could potentially
differentiate into polymeric IgA (pIgA)-producing plasma cells and
Figure 4. Histopathology of mouse lungs after challenge with M. catarrhalis. Mice were vaccinated intranasally (1 dose per week, 4 doses in
total) with either the adjuvant cholera toxin alone (1 mg/dose/mouse) or the combined conjugates AB (2.5 mg of each carbohydrate per dose per
mouse) plus adjuvant. One week after the last booster, mice were challenged with aerosolized M. catarrhalis. Mouse lungs were harvested 6 h later
for H&E staining. (A) Normal lung of a naive mouse; (B) Lung of the mouse administered with adjuvant only; (C) Lung of the mouse vaccinated with
the combined conjugates AB plus adjuvant. Arrows and arrowheads show infiltrating neutrophils and macrophages, respectively, in inflamed
lungs of mice after challenge by M. catarrhalis strains. Double arrowheads show proliferating lymphocytes in the lungs of conjugate-immunized
mice after challenge by M. catarrhalis strains. Original magnification6100;6400 (insets). (D) Histopathological lung injury scores for mice receiving
either the adjuvant only or the combined conjugates AB plus adjuvant followed with M. catarrhalis challenges. The scores were obtained from 10
random fields per mouse and 6 mice per group at magnification 6400. The categories used to generate the score were intra-alveolar infiltrates,
alveolar septal thickeness, alveolar hemorrhage, and intra-alveolar proteinaceous exudates. Data are expressed as mean 6 SD. *P,0.05 or
#P,0.05
indicates the significant difference vs naive mice or adjuvant only administered mice by ANOVA, respectively.
doi:10.1371/journal.pone.0029553.g004
A Conjugate Vaccine against Moraxella catarrhalis
PLoS ONE | www.plosone.org 6 December 2011 | Volume 6 | Issue 12 | e29553produce secretory IgA (SIgA) [24,25]. Anti-antigen specific SIgA
could enhance adherence of bacteria to mucus, thereby promoting
clearance by respiratory ciliary movement [24]. SIgA can also
inhibit bacterial agglutination, adherence for epithelial coloniza-
tion and penetration for invasion [26]. In addition to elevated
mucosal IgA secretion, intranasal immunization of the combined
LOS conjugates also significantly increased anti-antigen specific
serum IgG. The induced anti-LOS specific serum IgG demon-
strated a broad cross-reactivity toward all three prototypes of M.
catarrhalis strains under electron microscopy. Highly cross-reactive
serum IgG might extravasate into the infected respiratory mucosal
surface, promote phagocytosis of M. catarrhalis by alveolar
macrophages and infiltrating neutrophils, and facilitate bacterial
clearance by complement-mediated killing [27].
In addition to humoral responses, intranasal immunization of
the combined LOS conjugates also stimulated anti-antigen specific
cell-mediated immune responses in the lungs of vaccinated mice.
Pulmonary augmentation of Th1 type cytokines IFN-c and IL-12
could promote phagocytosis and respiratory burst thus leading to
killing of M. catarrhalis [28]. IFN-c could also induce the antibody
isotype mRc2a switch and result in IgG2a antibody production
that could potentially enhance bacterial clearance by complement-
mediated cytotoxicity [29,30]. Similarly, pulmonary IL-4, a typical
Th2 type cytokine was also significantly increased in the combined
conjugates vaccinated mice following challenges. IL-4 is pivotal in
B-cell switching from secretory IgM (SIgM) to IgG1 subclass
production and promotes IgG1, IgG2b, and IgA responses in mice
[29]. The augmentation of IL-4 has been linked to enhanced M.
catarrhalis clearance from mouse lungs [28]. In our present study,
enhanced pulmonary Th1 and Th2 cytokines not only correlated
significantly with increased lung clearance of M. catarrhalis, but also
correlated well with elevated mucosal IgA and serum IgG titers.
Moreover, intranasal immunization of the combined LOS
conjugates plus adjuvant also resulted in significantly less pro-
inflammatory cytokines such as TNF-a and mKC in the lungs of
vaccinated mice after M. catarrhalis infections than those admin-
istered with adjuvant only. The reduced pro-inflammatory TNF-a
and mKC correlated significantly with enhanced pulmonary
clearance of M. catarrhalis, suggesting vaccination of the combined
LOS conjugates could reduce M. catarrhalis induced pulmonary
inflammation. This was consistent with the histology data showing
that the combined conjugates vaccinated mouse lung structures
were more like those of the normal mouse lung.
In summary, intranasal vaccination with the combined
conjugates consisting of LOS from serotype A and B could
efficiently protect mice from the challenges of tested M. catarrhalis
strains of all three serotypes.
Acknowledgments
We are grateful to Dr. Eric J. Hansen at the University of Texas, Dallas,
TX for providing M. catarrhalis O35E and to John C. McMichael (retired
from Wyeth Vaccines, New York, NY) for providing M. catarrhalis LOSs.
We thank the NIH Fellows Editorial Board, Drs. David Robinson
(NIDCD/NIH, Rockville, MD), Gang Dong (NIAID/NIH, Bethesda,
MD), and Wei-Gang Hu (Defense Research & Development Canada-
Suffield, Medicine Hat, AB, Canada) for their review and comments
during the preparation of this manuscript.
Author Contributions
Conceived and designed the experiments: X-XG DR HX. Performed the
experiments: DR HX WZ FH RSP X-XG. Analyzed the data: DR HX X-
XG. Contributed reagents/materials/analysis tools: X-XG HX RSP SY
DJL. Wrote the paper: DR HX X-XG.
Figure 5. Immuno-electron microscopy of M. catarrhalis. Mice were vaccinated intranasally (1 dose per week, 4 doses in total) with either the
adjuvant cholera toxin alone (1 mg/dose/mouse) or the combined conjugates AB (2.5 mg of each carbohydrate per dose per mouse) plus adjuvant.
Mouse sera were collected at 1 week after the final immunization. Whole cells of strain 25238 (type A, A), 26397 (type B, B), or 26404 (type C, C) were
incubated with the mouse hyperimmune sera (1:400 dilution) followed by gold (5-nm diameter)-conjugated goat anti-mouse IgG. Whole cells of
strain 25238 (D) incubated with the corresponding pre-immune mouse sera (1:400 dilution) were included as a control. Scale bar, 100 nm.
doi:10.1371/journal.pone.0029553.g005
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